Q3 2017 SALES OF €88.3 MILLION, UP 5.2% AT CONSTANT EXCHANGE RATES

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates. Sales of Essential products, driver of the Group’s strategy, came to €41.9 million, up 16.7% like-for-like. All three territories posted strong growth at constant exchange rates, particularly Asia Pacific (10.5%), while Europe and the Americas both recorded 4.1% growth.  

Livestock product sales were up 6.1% (7.0% at constant exchange rates), while companion animal sales increased 1.6% as reported and 3.8% at constant exchange rates.  
 
For the nine months ended September 30, 2017, the Group posted sales of €264.0 million, up 2.5% from the previous year; growth at constant exchange rates amounted to 2.1%, with a positive currency impact of 0.4%. Growth continued to be driven by sales of Essential products, up 9.6% at constant exchange rates; these products accounted for 46.5% of sales for the nine months ended September 30, 2017 versus 43.5% in 2016. 
 
At September 30, 2017, Vetoquinol’s financial position remained very healthy. 
 
Vetoquinol wins 2 awards

Vetoquinol was ranked 3rd in the “Mid-Cap Corporate Governance” category at the 14th Agefi Grands Prix awards; Vetoquinol was also awarded 2nd prize by the 2017 Gaïa Index, a subsidiary of EthiFinance. These awards once again recognized Vetoquinol’s longstanding commitment to corporate social responsibility (CSR). 
  
Vetoquinol CEO Matthieu Frechin said: “As announced at our Investor Day on 27 September, we are pursuing our multi-specialist strategy geared towards 4 target species and 6 therapeutic domains, as well as the roll-out of our Essentials product range, which is growing fast on all our strategic markets.” 

Breakdown of sales 

 

 

> Press release

Latest news of vetoquinol